The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence
Oncology Reports · 2024
DOI: 10.3892/or.2024.8808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2024. Verfasst von Huan Gui und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Guizhou University, Guiyang, Guizhou 550025, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Receptors, Tumor Necrosis Factor, Type II, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Guizhou University, Guiyang, Guizhou 550025, P.R. China.
- NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China.
Zitieren
APA
Gui, H., Nie, Y., Yuan, H., Jing, Q., Li, L., Zhu, L., Chen, S., Wang, M., Wan, Q., Lv, H., Nie, Y., & Zhang, X. (2024). The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence. Oncology Reports. https://doi.org/10.3892/or.2024.8808
Vancouver
Gui H, Nie Y, Yuan H, Jing Q, Li L, Zhu L, et al. The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence. Oncology Reports. 2024. doi:10.3892/or.2024.8808
BibTeX
@article{Gui2024,
author = {Gui, Huan and Nie, Yujie and Yuan, Haohua and Jing, Qianyu and Li, Linzhao and Zhu, Lan and Chen, Shuanghui and Wang, Mengjiao and Wan, Quan and Lv, Hang and Nie, Yingjie and Zhang, Xiangyan},
title = {The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence},
journal = {Oncology Reports},
year = {2024},
doi = {10.3892/or.2024.8808}
}
EUVIMED